Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

Core Viewpoint - Qualigen Therapeutics, Inc. has received a deficiency notification from Nasdaq regarding its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2025, which may lead to delisting from the Nasdaq Stock Market [1][2]. Group 1 - The deficiency notification is based on Nasdaq Listing Rule 5250(c)(1), which mandates timely filing of periodic reports with the SEC [2]. - The Nasdaq Hearings Panel will consider this deficiency in its determination regarding the company's continued listing on the Nasdaq Capital Market [2][3]. - The company plans to present its compliance plan at the scheduled hearing and aims to file the Form 10-Q as soon as possible [4]. Group 2 - There is no assurance that the Panel will grant an extension or that the company will regain compliance with all listing requirements [4]. - The company is expected to address the deficiency during the hearing, and the Panel will make its decision based on the information presented [3].